Patents Assigned to Miralogx LLC
  • Patent number: 12758527
    Abstract: Compounds disclosed herein may exhibit antibacterial and anti-inflammatory properties. Pharmaceutical compositions containing the compound(s) may be used to treat bacterial infections, such as urinary tract infections, and/or disorders associated with chronic inflammation.
    Type: Grant
    Filed: September 9, 2024
    Date of Patent: October 13, 2026
    Assignee: Miralogx LLC
    Inventor: Jonnie R. Williams, Sr.
  • Patent number: 12760039
    Abstract: Pharmaceutical compounds have anti-inflammatory activity. A pharmaceutical composition may include a therapeutically effective amount of the compound(s) and a pharmaceutically acceptable vehicle. A method of treating hemochromatosis, hyperammonemia, or a disorder associated with chronic inflammation or a cancer, involves administering the pharmaceutical composition to an individual in need thereof. In another aspect, a method of inhibiting formation of metal oxides or reducing metal reactivity comprises contacting a metal with an effective amount of the compound(s).
    Type: Grant
    Filed: February 25, 2025
    Date of Patent: October 13, 2026
    Assignee: Miralogx LLC
    Inventor: Jonnie R. Williams, Sr.
  • Patent number: 12358892
    Abstract: Pharmaceutical compounds have anti-inflammatory activity and, in some aspects, may function as metalloenzyme inhibitors for the beneficial regulation of metalloproteins. A pharmaceutical composition may include a therapeutically effective amount of the compound(s) and a pharmaceutically acceptable vehicle. The pharmaceutical compositions may be useful for treating a disorder associated with chronic inflammation and/or metalloenzyme misregulation, including hemochromatosis, cancers such as breast cancer, or neurodegenerative diseases such as Alzheimer's disease.
    Type: Grant
    Filed: April 14, 2023
    Date of Patent: July 15, 2025
    Assignee: Miralogx LLC
    Inventor: Jonnie R. Williams, Sr.
  • Patent number: 12116341
    Abstract: Pharmaceutical compounds are disclosed which may be useful for treating asthma, ongoing lung disease, chronic obstructive pulmonary disease (COPD), chronic bronchitis, and/or emphysema. A pharmaceutical composition may include a therapeutically effective amount of the compound and a pharmaceutically acceptable vehicle therefor. The pharmaceutical composition may be administered for treating such disorders as asthma, ongoing lung disease, chronic obstructive pulmonary disease (COPD), chronic bronchitis, or emphysema.
    Type: Grant
    Filed: June 1, 2023
    Date of Patent: October 15, 2024
    Assignee: Miralogx LLC
    Inventor: Jonnie R. Williams, Sr.
  • Patent number: 11807604
    Abstract: Pharmaceutical compounds are disclosed which may be useful for treating asthma, ongoing lung disease, chronic obstructive pulmonary disease (COPD), chronic bronchitis, and/or emphysema. A pharmaceutical composition may include a therapeutically effective amount of the compound and a pharmaceutically acceptable vehicle therefor. The pharmaceutical composition may be administered for treating such disorders as asthma, ongoing lung disease, chronic obstructive pulmonary disease (COPD), chronic bronchitis, or emphysema.
    Type: Grant
    Filed: February 15, 2023
    Date of Patent: November 7, 2023
    Assignee: Miralogx LLC
    Inventor: Jonnie R. Williams, Sr.
  • Patent number: 11767329
    Abstract: Antibacterial compounds are shown and described. In one aspect, a pharmaceutical composition includes a therapeutically effective amount of an antibacterial compound and a pharmaceutically acceptable vehicle therefor. In another aspect, a method of treating a bacterial infection involves administering the pharmaceutical composition to an individual in need thereof.
    Type: Grant
    Filed: August 1, 2022
    Date of Patent: September 26, 2023
    Assignee: Miralogx LLC
    Inventor: Jonnie R. Williams, Sr.
  • Publication number: 20230295125
    Abstract: Pharmaceutical compounds have anti-inflammatory activity and, in some aspects, may function as metalloenzyme inhibitors for the beneficial regulation of metalloproteins. A pharmaceutical composition may include a therapeutically effective amount of the compound(s) and a pharmaceutically acceptable vehicle. The pharmaceutical compositions may be useful for treating a disorder associated with chronic inflammation and/or metalloenzyme misregulation, including hemochromatosis, cancers such as breast cancer, or neurodegenerative diseases such as Alzheimer’s disease.
    Type: Application
    Filed: April 14, 2023
    Publication date: September 21, 2023
    Applicant: Miralogx LLC
    Inventor: Jonnie R. Williams, SR.